Biodegradable Lipid Compound for Low-Toxicity Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposomes for drug delivery lack biodegradability and have high cytotoxicity, limiting their effectiveness and versatility in treating various diseases, particularly in gene transfer applications where high biocompatibility and low toxicity are required.
Innovation Solution
A novel biodegradable lipid compound with a non-cationic aliphatic group and ester structure is developed, which forms a liposome with improved biodegradability and reduced toxicity, enhancing the transfection rate of active agents like nucleic acids by suppressing protein bonding and aggregation, and is combined with a lipid particle containing a membrane-forming and aggregation-reducing lipid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional lipids are used to constitute liposomes, then the liposomes can be formed with membrane structure, but the liposomes exhibit high cytotoxicity and poor biodegradability
Solution Approach 1:
The patent modifies the chemical structure of lipid molecules by introducing biodegradable ester bonds and non-cationic aliphatic groups, changing the chemical parameters of the lipid to achieve both low cytotoxicity and high biodegradability simultaneously
Solution Approach 2:
The patent creates composite lipid structures combining hydrophilic head groups with biodegradable ester-linked hydrophobic tails, forming a composite material that exhibits both biocompatibility and biodegradability in the liposome membrane
2Adaptability or versatility
If lipid mixture is used to add remarkable characteristics to liposomes, then the liposome functionality is enhanced, but the complexity of lipid composition increases
Solution Approach 1:
The patent designs a universal lipid structure with ester bonds that can perform multiple functions including membrane formation, biodegradation, and controlled release, reducing the need for complex lipid mixtures while maintaining versatility
Solution Approach 2:
The patent segments the lipid molecule into distinct functional regions (hydrophilic head, ester bond linkage, hydrophobic tail) that can independently perform specific functions, allowing simplified composition with enhanced characteristics
3Productivity
If liposomes are used for gene transfer, then the delivery of nucleic acids is achieved, but the transfection rate is limited by protein bonding and aggregation
Solution Approach 1:
The patent converts the potential harm of protein bonding into a benefit by designing non-cationic aliphatic groups that specifically suppress unwanted protein aggregation while maintaining necessary biological interactions, thereby enhancing transfection rate
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid compound achieves higher transfection rates of nucleic acids with reduced cytotoxicity and improved biocompatibility, extending the in vivo half-life and stability of liposomes, allowing for efficient delivery of therapeutic agents.
Implementation Method 1
L is a single bond or an aliphatic group containing no nitrogen, and contains an ester structure selected from the group consisting of -C(=O)-O-, -O-C(=O)-, -O-C(=O)-O-
Data Source
Figure 1
Figure 2~3
AI summary
The compound according to the present embodiment is represented by the following formula (1): Q-L-CHR2 (1) (wherein, Q is a non-cationic aliphatic group that does not contain nitrogen but contains oxy; L is a single bond or an aliphatic group containing no nitrogen; Rs are C12-C24 aliphatic group, the same or different; and at least one R contains, in the main chain or side chain thereof, a linking group LR selected from the group consisting of -C(=O)-O-, -O-C(=O)-, -O-C(=O)-O-, -S-C(=O)-, -C(=O)-S-, -C(=O)-NH-, and -NH-C(=O)-).